Jay Lichter - Net Worth and Insider Trading

Jay Lichter Net Worth

The estimated net worth of Jay Lichter is at least $1.1 Billion dollars as of 2024-05-09. Jay Lichter is the Director, 10% Owner of Janux Therapeutics Inc and owns about 9,716,563 shares of Janux Therapeutics Inc (JANX) stock worth over $538 Million. Jay Lichter is the Director, 10% Owner of Synthorx Inc and owns about 7,567,513 shares of Synthorx Inc (THOR) stock worth over $515 Million. Jay Lichter is also the Director of Otonomy Inc and owns about 0 shares of Otonomy Inc (OTIC) stock worth over $0. Details can be seen in Jay Lichter's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Jay Lichter has not made any transactions after 2023-11-13 and currently still holds the listed stock(s).

Transaction Summary of Jay Lichter

To

Jay Lichter Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jay Lichter owns 4 companies in total, including Otonomy Inc (OTIC) , Synthorx Inc (THOR) , and Aratana Therapeutics Inc (PETX) among others .

Click here to see the complete history of Jay Lichter’s form 4 insider trades.

Insider Ownership Summary of Jay Lichter

Ticker Comapny Transaction Date Type of Owner
OTIC Otonomy Inc 2021-03-03 director
THOR Synthorx Inc 2020-01-23 director
PETX Aratana Therapeutics Inc 2015-07-15 director
2023-11-13 director & 10 percent owner

Jay Lichter Latest Holdings Summary

Jay Lichter currently owns a total of 3 stocks. Among these stocks, Jay Lichter owns 9,716,563 shares of Janux Therapeutics Inc (JANX) as of November 13, 2023, with a value of $538 Million and a weighting of 51.12%. Jay Lichter owns 7,567,513 shares of Synthorx Inc (THOR) as of December 11, 2018, with a value of $515 Million and a weighting of 48.88%. Jay Lichter also owns 0 shares of Otonomy Inc (OTIC) as of March 3, 2021, with a value of $0 and a weighting of 0%.

Latest Holdings of Jay Lichter

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
JANX Janux Therapeutics Inc 2023-11-13 9,716,563 55.37 538,006,093
THOR Synthorx Inc 2018-12-11 7,567,513 67.99 514,515,209
OTIC Otonomy Inc 2021-03-03 0 0.01 0

Holding Weightings of Jay Lichter


Jay Lichter Form 4 Trading Tracker

According to the SEC Form 4 filings, Jay Lichter has made a total of 1 transactions in Janux Therapeutics Inc (JANX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Janux Therapeutics Inc is the acquisition of 849,854 shares on November 13, 2023, which cost Jay Lichter around $5 Million.

According to the SEC Form 4 filings, Jay Lichter has made a total of 0 transactions in Synthorx Inc (THOR) over the past 5 years. The most-recent trade in Synthorx Inc is the acquisition of 545,455 shares on December 11, 2018, which cost Jay Lichter around $6 Million.

According to the SEC Form 4 filings, Jay Lichter has made a total of 3 transactions in Otonomy Inc (OTIC) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Otonomy Inc is the sale of 321,180 shares on March 3, 2021, which brought Jay Lichter around $867,186.

Insider Trading History of Jay Lichter

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jay Lichter Trading Performance

GuruFocus tracks the stock performance after each of Jay Lichter's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jay Lichter is 17.63%. GuruFocus also compares Jay Lichter's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jay Lichter within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jay Lichter's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jay Lichter

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 18.78
Relative Return to S&P 500(%) 16.2

Jay Lichter Ownership Network

Ownership Network List of Jay Lichter

No Data

Ownership Network Relation of Jay Lichter


Jay Lichter Owned Company Details

What does Otonomy Inc do?

Who are the key executives at Otonomy Inc?

Jay Lichter is the director of Otonomy Inc. Other key executives at Otonomy Inc include Chief Scientific Officer Alan Charles Foster , director & President & CEO David Allen Weber , and CFO/Ch. Business Offcr & Sec. Paul E Cayer .

Otonomy Inc (OTIC) Insider Trades Summary

Over the past 18 months, Jay Lichter made no insider transaction in Otonomy Inc (OTIC). Other recent insider transactions involving Otonomy Inc (OTIC) include a net sale of 42,242 shares made by Vickie L Capps ,

In summary, during the past 3 months, insiders sold 0 shares of Otonomy Inc (OTIC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 42,242 shares of Otonomy Inc (OTIC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 42,242 shares.

Otonomy Inc (OTIC)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Otonomy Inc Insider Transactions

No Available Data

Jay Lichter Mailing Address

Above is the net worth, insider trading, and ownership report for Jay Lichter. You might contact Jay Lichter via mailing address: C/o Aratana Therapeutics, Inc., 11400 Tomahawk Creek Parkway, Suite 340, Leawood Ks 66211.

Discussions on Jay Lichter

No discussions yet.